Lentiviral-mediated gene therapy restores B cell tolerance in Wiskott-Aldrich syndrome patients

Journal of Clinical Investigation

Volumn 125, Issue 10, 2015, Pages 3941-3951

  Pala, Francesca ^a,b   Morbach, Henner ^b   Castiello, Maria Carmina ^a   Schickel, Jean Nicolas ^b   Scaramuzza, Samantha ^a   Chamberlain, Nicolas ^b   Cassani, Barbara ^c,d   Glauzy, Salome ^b   Romberg, Neil ^b   Candotti, Fabio ^e   Aiuti, Alessandro ^a,f   Bosticardo, Marita ^a   Villa, Anna ^a,d   Meffre, Eric ^b  

^a SAN RAFFAELE SCIENTIFIC INSTITUTE   (Italy)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^d CNR   (Italy)

^e NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^f UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

B LYMPHOCYTE RECEPTOR; RECOMBINANT ANTIBODY; HYBRID PROTEIN; LYMPHOCYTE ANTIGEN RECEPTOR; WAS PROTEIN, HUMAN; WISKOTT ALDRICH SYNDROME PROTEIN;

ARTICLE; B LYMPHOCYTE; CELL CLONE; CELL MIGRATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; LENTIVIRINAE; PRE B LYMPHOCYTE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION; VIRAL GENE THERAPY; WISKOTT ALDRICH SYNDROME; ADULT; AMINO ACID SEQUENCE; BONE MARROW; CHILD; DEFICIENCY; GENE THERAPY; GENE VECTOR; GENETICS; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; MALE; MOLECULAR GENETICS; PATHOLOGY; PRESCHOOL CHILD; THERAPEUTIC USE; WISKOTT-ALDRICH SYNDROME;

ADULT; AMINO ACID SEQUENCE; B-LYMPHOCYTES; BONE MARROW; CHILD; CHILD, PRESCHOOL; CLONAL DELETION; CLONE CELLS; GENETIC THERAPY; GENETIC VECTORS; HUMANS; IMMUNE TOLERANCE; LENTIVIRUS; MALE; MOLECULAR SEQUENCE DATA; RECEPTORS, ANTIGEN, B-CELL; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES, REGULATORY; WISKOTT-ALDRICH SYNDROME; WISKOTT-ALDRICH SYNDROME PROTEIN;

EID: 84943327950     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI82249     Document Type: Article

References (44)

1. Bosticardo M, Marangoni F, Aiuti A, Villa A, Grazia Roncarolo M. Recent advances in understanding the pathophysiology of Wiskott-Aldrich syndrome. Blood. 2009;113(25):6288-6295.
2. Thrasher AJ, Burns SO. WASP: a key immunological multitasker. Nat Rev Immunol. 2010;10(3):182-192.
3. Imai K, et al. Clinical course of patients with WASP gene mutations. Blood. 2004;103(2):456-464.
4. Catucci M, Castiello MC, Pala F, Bosticardo M, Villa A. Autoimmunity in Wiskott-Aldrich syndrome: an unsolved enigma. Front Immunol. 2012;3:209.
5. Marangoni F, et al. WASP regulates suppressor activity of human and murine CD4(+)CD25(+) FOXP3(+) natural regulatory T cells. J Exp Med. 2007;204(2):369-380.
6. Maillard MH, et al. The Wiskott-Aldrich syndrome protein is required for the function of CD4(+)CD25(+)Foxp3(+) regulatory T cells. J Exp Med. 2007;204(2):381-391.
7. Adriani M, et al. Impaired in vitro regulatory T cell function associated with Wiskott-Aldrich syndrome. Clin Immunol. 2007;124(1):41-48.
8. Humblet-Baron S, et al. Wiskott-Aldrich syndrome protein is required for regulatory T cell homeostasis. J Clin Invest. 2007;117(2):407-418.
9. Becker-Herman S, et al. WASp-deficient B cells play a critical, cell-intrinsic role in triggering autoimmunity. J Exp Med. 2011;208(10):2033-2042.
10. Recher M, et al. B cell-intrinsic deficiency of the Wiskott-Aldrich syndrome protein causes severe abnormalities of the peripheral B cell compartment in mice. Blood. 2012;119(12):2819-2828.
11. Bosticardo M, et al. Lentiviral-mediated gene therapy leads to improvement of B cell functionality in a murine model of Wiskott-Aldrich syndrome. J Allergy Clin Immunol. 2011;127(6):1376-1384.
12. Facchetti F, et al. Defective actin polymerization in EBV-transformed B cell lines from patients with the Wiskott-Aldrich syndrome. J Pathol. 1998;185(1):99-107.
13. Sic H, et al. Sphingosine-1-phosphate receptors control B cell migration through signaling components associated with primary immunodeficiencies, chronic lymphocytic leukemia, and multiple sclerosis. J Allergy Clin Immunol. 2014;134(2):420-428.
14. Castiello MC, et al. Wiskott-Aldrich Syndrome protein deficiency perturbs the homeostasis of B cell compartment in humans. J Autoimmun. 2014;50:42-50.
15. Sullivan KE, Mullen CA, Blaese RM, Winkelstein JA. A multiinstitutional survey of the Wiskott-Aldrich syndrome. J Pediatr. 1994;125(6 pt 1):876-885.
16. Buchbinder D, Nugent DJ, Fillipovich AH. Wiskott-Aldrich syndrome: diagnosis, current management, and emerging treatments. Appl Clin Genet. 2014;7:55-66.
17. Simon KL, Anderson SM, Garabedian EK, Moratto D, Sokolic RA, Candotti F. Molecular and phenotypic abnormalities of B lymphocytes in patients with Wiskott-Aldrich syndrome. J Allergy Clin Immunol. 2013;133(3):896-899.
18. Isnardi I, et al. Complement receptor 2/CD21-human naive B cells contain mostly autoreactive unresponsive clones. Blood. 2010;115(24):5026-5036.
19. Silberstein LE, et al. Variable region gene analysis of pathologic human autoantibodies to the related i and I red blood cell antigens. Blood. 1991;78(9):2372-2386.
20. Pascual V, et al. Nucleotide sequence analysis of the V regions of two IgM cold agglutinins. Evidence that the VH4-21 gene segment is responsible for the major cross-reactive idiotype. J Immunol. 1991;146(12):4385-4391.
21. Wardemann H, Yurasov S, Schaefer A, Young JW, Meffre E, Nussenzweig MC. Predominant autoantibody production by early human B cell precursors. Science. 2003;301(5638):1374-1377.
22. Ng YS, Wardemann H, Chelnis J, Cunningham-Rundles C, Meffre E. Bruton's tyrosine kinase is essential for human B cell tolerance. J Exp Med. 2004;200(7):927-934.
23. Isnardi I, et al. IRAK-4-and MyD88-dependent pathways are essential for the removal of developing autoreactive B cells in humans. Immunity. 2008;29(5):746-757.
24. Romberg N, et al. CVID-associated TACI mutations affect autoreactive B cell selection and activation. J Clin Invest. 2013;123(10):4283-4293.
25. Meffre E. The establishment of early B cell tolerance in humans: lessons from primary immunodeficiency diseases. Ann N Y Acad Sci. 2011;1246:1-10.
26. Kinnunen T, et al. Accumulation of peripheral autoreactive B cells in the absence of functional human regulatory T cells. Blood. 2013;121(9):1595-1603.
27. Herve M, et al. CD40 ligand and MHC class II expression are essential for human peripheral B cell tolerance. J Exp Med. 2007;204(7):1583-1593.
28. Menard L, et al. Signaling lymphocytic activation molecule (SLAM)/SLAM-associated protein pathway regulates human B cell tolerance. J Allergy Clin Immunol. 2014;133(4):1149-1161.
29. Janssen E, et al. Dedicator of cytokinesis 8-deficient patients have a breakdown in peripheral B cell tolerance and defective regulatory T cells. J Allergy Clin Immunol. 2014;134(6):1365-1374.
30. Aiuti A, et al. Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome. Science. 2013;341(6148):1233151.
31. Castiello MC, et al. B cell reconstitution after lentiviral vector-mediated gene therapy in patients with Wiskott-Aldrich syndrome. J Allergy Clin Immunol. 2015;S0091-6749(3)(15)00179-7.
32. Jabara HH, et al. DOCK8 functions as an adaptor that links TLR-MyD88 signaling to B cell activation. Nat Immunol. 2012;13(6):612-620.
33. Saadoun D, et al. Expansion of autoreactive unresponsive CD21-/low B cells in Sjogren's syndrome-associated lymphoproliferation. Arthritis Rheum. 2013;65(4):1085-1096.
34. Terrier B, et al. Expansion of functionally anergic CD21-/low marginal zone-like B cell clones in hepatitis C virus infection-related autoimmunity. J Immunol. 2011;187(12):6550-6563.
35. Meyers G, et al. Activation-induced cytidine deaminase (AID) is required for B cell tolerance in humans. Proc Natl Acad Sci U S A. 2011;108(28):11554-11559.
36. Sauer AV, et al. Alterations in the adenosine metabolism and CD39/CD73 adenosinergic machinery cause loss of Treg cell function and autoimmunity in ADA-deficient SCID. Blood. 2012;119(6):1428-1439.
37. Prete F, et al. Wiskott-Aldrich syndrome proteinmediated actin dynamics control type-I interferon production in plasmacytoid dendritic cells. J Exp Med. 2013;210(2):355-374.
38. Batista FD, Treanor B, Harwood NE. Visualizing a role for the actin cytoskeleton in the regulation of B cell activation. Immunol Rev. 2010;237(1):191-204.
39. Song W, Liu C, Upadhyaya A. The pivotal position of the actin cytoskeleton in the initiation and regulation of B cell receptor activation. Biochim Biophys Acta. 2014;1838(2):569-578.
40. Adriani M, et al. Defective inhibition of B cell proliferation by Wiskott-Aldrich syndrome protein-deficient regulatory T cells. Blood. 2011;117(24):6608-6611.
41. Cannon JL, Burkhardt JK. Differential roles for Wiskott-Aldrich syndrome protein in immune synapse formation and IL-2 production. J Immunol. 2004;173(3):1658-1662.
42. Cianferoni A, et al. Defective nuclear translocation of nuclear factor of activated T cells and extracellular signal-regulated kinase underlies deficient IL-2 gene expression in Wiskott-Aldrich syndrome. J Allergy Clin Immunol. 2005;116(6):1364-1371.
43. Trifari S, et al. Defective Th1 cytokine gene transcription in CD4+ and CD8+ T cells from Wiskott-Aldrich syndrome patients. J Immunol. 2006;177(10):7451-7461.
44. Meffre E, Schaefer A, Wardemann H, Wilson P, Davis E, Nussenzweig MC. Surrogate light chain expressing human peripheral B cells produce self-reactive antibodies. J Exp Med. 2004;199(1):145-150.